Can-Fite BioPharma

A patient treated with Namodenoson in Can-Fite's Phase II Liver Cancer Study has shown an 8-year overall survival with complete response. Namodenoson, with Orphan Drug and Fast Track status, is now in a pivotal Phase III study for advanced HCC, aiming to prolong survival. The drug's unique action against tumor cells while protecting normal liver cells underpins the trial's rationale.

Can-Fite BioPharma announced a patient treated with Namodenoson in a Phase II Liver Cancer Study achieved 8 years of overall survival with complete response.

Switch Market flag for country-specific data. Right-click for chart options. Use arrows to navigate symbols.

Can-Fite BioPharma announces first patient dosed in Phase IIa trial for advanced pancreatic adenocarcinoma, evaluating Namodenoson's safety and efficacy. Namodenoson, an A3 adenosine receptor agonist, has received Orphan Drug Designation from the US FDA.

Can-Fite BioPharma announces first patient dosing in Phase IIa pancreatic cancer trial, evaluating Namodenoson's safety and clinical activity.

Can-Fite BioPharma Ltd. (CANF) develops oral therapeutics targeting A3AR for cancer, liver, and inflammatory diseases. Key drugs include Piclidenoson (Phase III psoriasis) and Namodenoson (Phase III HCC, Phase IIb NASH). Based in Israel, the company leverages partnerships to advance drug development.

The FDA granted namodenoson an orphan drug designation for pancreatic cancer treatment. Namodenoson, a small, orally bioavailable drug, targets A3 adenosine receptors on cancer cells, inducing apoptosis. A phase 2 study is planned to evaluate its safety and clinical activity in advanced pancreatic cancer patients. Preclinical studies showed namodenoson significantly inhibited pancreatic cancer cell growth and modulated signaling pathways.

Can-Fite BioPharma's Namodenoson granted Orphan Drug Designation by FDA for pancreatic cancer, with plans to start Phase II study by year-end.